Airshow China: Controversial cruise missile breaks cover
A new cruise missile named the CX-1 garnered attention and courted controversy at Airshow China in Zhuhai.
A supersonic product from the 1st Academy of the China Aerospace Science and Technology Corporation (CASC), the missile was likely developed using technology related to Yakhont cruise missiles that were obtained by China in the wake of the Soviet Union’s collapse.
The reason the CX-1 caused such a flurry is that the joint Indo-Russian BrahMos missile was also originally based on Yakhont technology, helping to explain the two types’ uncanny resemblance.
However, what is angering both Russia and India is that China is
Already have an account? Log in
Want to keep reading this article?
More from Land Warfare
-
DSEI 2025: OpenWorks launches new system for on-the-move targeting
Vision Pace uses OpenWorks’ artificial intelligence (AI) classifiers and trackers to detect, track and identify multiple targets in land and naval applications for air defence.
-
DSEI 2025: Patria’s FAMOUS becomes TRACKX with production ready before end of 2027
The first two Technology Test Beds (TTBs) have been completed and put through a series of company trials including sand, snow, swamp, forest and tarmac.
-
DSEI 2025: General Dynamics firms up Ajax for potential British Army IFV requirement
Following the cancellation of the Lockheed Martin UK Warrior Capability Sustainment Programme (WCSP), the British Army will have a serious capability gap when the current Warrior infantry fighting vehicle (IFV) is soon phased out of service.
-
DSEI 2025: Trials completed for new version of Tridon air defence gun
Less than two years ago, Sweden’s BAE Systems Bofors announced it was developing a new 40mm short-range air defence system using internal research and development funding, calling it the Tridon Mk2.
-
DSEI 2025: Rheinmetall adds Lockheed Martin missile punch to Fuchs vehicle
The combination of the Rheinmetall platform with Lockheed Martin missiles is seen as the bringing together of mature systems to provide a capability in the medium term, but trials could be as long as 12 months away.